A Randomized Feasibility Trial of Stereotactic Prostate Radiation Therapy With or Without Elective Nodal Irradiation in High-Risk Localized Prostate Cancer (SPORT Trial)

Purpose: The aim of this study was to establish the feasibility of a randomized clinical trial comparing SABR with prostateonly (P-SABR) or with prostate plus pelvic lymph nodes (PPN-SABR) in patients with unfavorable intermediate- or high-risk localized prostate cancer and to explore potential toxicity biomarkers.Methods and Materials: Thirty adult men with at least 1 of the following features were randomized 1:1 to P-SABR or PPNSABR: clinical magnetic resonance imaging stage T3a N0 M0, Gleason score >= 7 (4+3), and prostate-specific antigen >20 ng/mL. P-SABR patients received 36.25 Gy/5 fractions/29 days, and PPN-SABR patients received 25 Gy/5 fractions to pelvic nodes, with the final cohort receiving a boost to the dominant intraprostatic lesion of 45 to 50 Gy. Phosphorylated gammaH2AX (gH2AX) foci numbers, citrulline levels, and circulating lymphocyte counts were quantified. Acute toxicity information (Common Terminology Criteria for Adverse Events, version 4.03) was collected weekly at each treatment and at 6 weeks and 3 months. Physician-reported late Radiation Therapy Oncology Group (RTOG) toxicity was recorded from 90 days to 36months postcompletion of SABR. Patient-reported quality of life (Expanded Prostate Cancer Index Composite and Interna-tional Prostate Symptom Score) scores were recorded with each toxicity time point.Results: The target recruitment was achieved, and treatment was successfully delivered in all patients. A total of 0% and 6.7% (P-SABR) and 6.7% and 20.0% (PPN-SABR) experienced acute grade >= 2 gastrointestinal (GI) and genitourinary (GU) toxicity, respectively. At 3 years, 6.7% and 6.7% (P-SABR) and 13.3% and 33.3% (PPN-SABR) had experienced late grade >= 2 GI and GU toxicity, respectively. One patient (PPN-SABR) had late grade 3 GU toxicity (cystitis and hematuria). No other grade >= 3 toxicity was observed. In addition, 33.3% and 60% (P-SABR) and 64.3% and 92.9% (PPN-SABR) experienced a minimally clin-ically important change in late Expanded Prostate Cancer Index Composite bowel and urinary summary scores, respectively. yH2AX foci numbers at 1 hour after the first fraction were significantly higher in the PPN-SABR arm compared with the P-SABR arm (P = .04). Patients with late grade >= 1 GI toxicity had significantly greater falls in circulating lymphocytes (12 weeks post-radiation therapy, P = .01) and a trend toward higher yH2AX foci numbers (P = .09) than patients with no late toxicity. Patients with late grade >= 1 bowel toxicity and late diarrhea experienced greater falls in citrulline levels (P = .05).Conclusions: A randomized trial comparing P-SABR with PPN-SABR is feasible with acceptable toxicity. Correlations of yH2AX foci, lymphocyte counts, and citrulline levels with irradiated volume and toxicity suggest potential as predictive bio-markers. This study has informed a multicenter, randomized, phase 3 clinical trial in the United Kingdom. (c) 2023 Elsevier Inc. All rights reserved.